CADTH Canadian Drug Expert Committee Recommendation: Teduglutide (Revestive — Shire Pharmaceuticals Ireland Limited): Indication: treatment of adults and pediatric patients 1 year of age and above with Short Bowel Syndrome who are dependent on parenteral support [Internet]

Review
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Nov.
CADTH Common Drug Reviews.
No abstract available

Publication types

  • Review

Grants and funding

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.